Quarterly Result5 Aug 2025, 04:27 pm
Gland Pharma Reports Q1 2025 Financial Results with 8.81% Profit Growth
AI Summary
Gland Pharma Limited, a leading pharmaceutical company, has reported its unaudited financial results for the quarter ended June 30, 2025. The company's revenue from operations stands at INR 15,056.22 million, representing a growth of 3.78% compared to the previous quarter. The profit before tax stands at INR 960.22 million, reflecting a significant increase of 14.57% compared to the previous quarter. The total comprehensive income attributable to the owners of the company stands at INR 7,539.13 million.
Key Highlights
- Revenue from operations stands at INR 15,056.22 million, representing a growth of 3.78% compared to the previous quarter.
- Profit before tax stands at INR 960.22 million, reflecting a significant increase of 14.57% compared to the previous quarter.
- Total comprehensive income attributable to the owners of the company stands at INR 7,539.13 million.
- The company granted 556,832 employee stock options at an exercise price of INR 773.30 and 286,853 employee stock options at an exercise price of INR 1 to its employees.
- The Group is engaged in the manufacture and sale of 'Pharmaceuticals', which constitutes a single reportable business segment as per Ind AS 108- ‘Operating Segments’.